Glynos Konstantinos is Pulmonologist - Tuberculosis specialist in the private sector running his pulmonological office since 2015 in Nea Smyrne. He works as a medical advisor/manager and currently as Real-World Evidence (RWE) lead in GlaxoSmithKline (GSK). Since 2015, he has been working as medical advisor in the Respi department, for the Ellipta products (Relvar, Incruse, Anoro) and Nucala. Also he has been challenged in managing and couching MSL. His work has been recognized in GSK for the high accountability and teamwork in designing and executing customer centric solutions to overcome challenges and create new opportunities, especially in the era of Evidence Generation, conducting ISSs in Greece and designed, initiated and reviewed a GSK sponsored study titled “RElight” in collaboration with Greek the Hellenic Thoracic Society and also designed and initiated a European collaboration in evidence generation for patients with nasal polyps and asthma (“RESPONSE” and “MEPOLYP”). Previously, he has been working as a clinical consultant in the Intensive Care Unit of "Evangelismos" hospital, and as a post doc-research associate at the University Hospital of Ghent-Belgium and in the laboratory of Molecular Pharmacology of the University of Patras Pharmaceutical Division. His research work, focused on pathophysiology/molecular biology in obstructive airways disease (asthma and COPD), lung injury and sepsis, published in international peer-reviewed journals and awarded by the Greek and European Respiratory Society.
SAVE
(6)
